Effects of the Class III antiarrhythmic agent dofetilide (UK‐68,798) on L‐type calcium current from rabbit ventricular myocytes
暂无分享,去创建一个
J. Hancox | H. Witchel | D. Leishman | D. Leishman | A. A. Paul | J. Hancox | H. Witchel
[1] M. Malik,et al. QTc Interval as a Guide to Select Those Patients With Congestive Heart Failure and Reduced Left Ventricular Systolic Function Who Will Benefit From Antiarrhythmic Treatment With Dofetilide , 2001, Circulation.
[2] Itsuo Kodama,et al. Short- and Long-Term Effects of Amiodarone on the Two Components of Cardiac Delayed Rectifier K+ Current , 2001, Circulation.
[3] M. Malik,et al. QT Dispersion Has No Prognostic Information for Patients With Advanced Congestive Heart Failure and Reduced Left Ventricular Systolic Function , 2001, Circulation.
[4] H. Witchel,et al. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide. , 2001, Biochemical and biophysical research communications.
[5] Kenneth Egstrup,et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial , 2000, The Lancet.
[6] R. Falk,et al. Dofetilide: a new pure class III antiarrhythmic agent. , 2000, American heart journal.
[7] L. Køber,et al. Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation , 2000, Expert opinion on investigational drugs.
[8] J. Hancox,et al. Familial And Acquired Long QT Syndrome And The Cardiac Rapid Delayed Rectifier Potassium Current , 2000, Clinical and experimental pharmacology & physiology.
[9] J. Hancox,et al. Inhibition by nickel of the L-type Ca channel in guinea pig ventricular myocytes and effect of internal cAMP. , 2000, American journal of physiology. Heart and circulatory physiology.
[10] A. Pappano,et al. Comparison of L-type calcium channel blockade by nifedipine and/or cadmium in guinea pig ventricular myocytes. , 2000, The Journal of pharmacology and experimental therapeutics.
[11] J. Hancox,et al. Antiarrhythmics—from cell to clinic: past, present, and future , 2000, Heart.
[12] A. Bril,et al. Electrophysiological characterization of BRL-32872 in canine Purkinje fiber and ventricular muscle. Effect on early after-depolarizations and repolarization dispersion. , 1999, European journal of pharmacology.
[13] A. Camm,et al. What Should We Expect From the Next Generation of Antiarrhythmic Drugs? , 1999, Journal of cardiovascular electrophysiology.
[14] J. Hancox,et al. EFFECT OF PHOSPHORYLATION ON L‐TYPE CALCIUM CURRENT IN VENTRICULAR MYOCYTES DIALYSED WITH PROTEOLYTIC ENZYMES , 1999, Clinical and experimental pharmacology & physiology.
[15] C. January,et al. Proarrhythmia Related to Prolongation of Repolarization: Mechanisms, Monitoring, Prevention, and Management , 1998 .
[16] Harry J. Witchel,et al. Time course and voltage dependence of expressed HERG current compared with native ”rapid” delayed rectifier K current during the cardiac ventricular action potential , 1998, Pflügers Archiv.
[17] A. Bril,et al. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide. , 1998, Cardiovascular research.
[18] A. Brown,et al. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. , 1996, Circulation.
[19] Bertram Pitt,et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.
[20] R. Fischmeister,et al. Binding constants determined from Ca2+ current responses to rapid applications and washouts of nifedipine in frog cardiac myocytes. , 1996, The Journal of physiology.
[21] D. Snyders,et al. High affinity open channel block by dofetilide of HERG expressed in a human cell line. , 1996, Molecular pharmacology.
[22] H. Duff,et al. [3H]dofetilide binding: biological models that manifest solely the high or the low affinity binding site. , 1996, Journal of molecular and cellular cardiology.
[23] R. Campbell,et al. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. , 1995, The American journal of cardiology.
[24] T. Ogura,et al. Action potentials, ionic currents and cell water in guinea pig ventricular preparations exposed to dimethyl sulfoxide. , 1995, The Journal of pharmacology and experimental therapeutics.
[25] M. Kanno,et al. Effects of dofetilide on membrane currents in sinoatrial node cells of rabbit. , 1995, Japanese journal of pharmacology.
[26] G. Yellen,et al. Visual identification of individual transfected cells for electrophysiology using antibody-coated beads. , 1994, BioTechniques.
[27] J. Brachmann,et al. Differential Effects of the New Class III Agent Dofetilide on Potassium Currents in Guinea Pig Cardiomyocytes , 1994, Journal of cardiovascular pharmacology.
[28] Jules C. Hancox,et al. A method for isolating rabbit atrioventricular node myocytes which retain normal morphology and function. , 1993, The American journal of physiology.
[29] M. Sanguinetti,et al. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. , 1993, Circulation research.
[30] G. Butrous,et al. Dofetilide, A Novel Class III Antiarrhythmic Agent , 1992, Journal of cardiovascular pharmacology.
[31] Robert Lemery,et al. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. , 1992, The New England journal of medicine.
[32] H L Greene,et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.
[33] J. Arrowsmith,et al. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. , 1991, The Journal of pharmacology and experimental therapeutics.
[34] J. Jalife,et al. Cardiac Electrophysiology: From Cell to Bedside , 1990 .
[35] M. Sanguinetti,et al. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.
[36] Craig T. January,et al. Early Afterdepolarizations: Mechanism of Induction and Block A Role for L‐Type Ca2+ Current , 1989, Circulation research.
[37] W. Rogers,et al. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.